{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:47Z","timestamp":1787026547270,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>BRAF V600E mutation defines a rare but targetable subset of NSCLC. We report a 70-year-old non-smoking woman with unknown primary lung adenocarcinoma presenting with multistation mediastinal lymph-node metastases and massive malignant pleural and pericardial effusions. Molecular profiling showed BRAF V600E mutation and high PD-L1 expression(TPS 90%, CPS 95). The patient received combined dabrafenib, trametinib, and pembrolizumab with close safety monitoring, achieving rapid tumor control and complete remission by six months with manageable toxicity. This case suggests that early integration of PD-1 blockade with BRAF\/MEK inhibition treatment may benefit selected patients and underscores the value of comprehensive molecular and immunohistochemical assessment to guide individualized therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1666461","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:27:15Z","timestamp":1763360835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Response to dabrafenib and trametinib combined with pembrolizumab in an elderly patient with lung adenocarcinoma of unknown primary harboring BRAF V600E mutation and high PD-L1 expression: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Nan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00996-1","article-title":"Advancing therapeutics in small-cell lung cancer","volume":"6","author":"Thomas","year":"2025","journal-title":"Nat Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.05.014","article-title":"Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions","volume":"169","author":"Riudavets","year":"2022","journal-title":"Lung Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122205","article-title":"Promising combinatorial therapeutic strategies against non-small cell lung cancer","volume":"16","author":"Kaur","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61178-1","article-title":"Cancer of unknown primary site","volume":"379","author":"Pavlidis","year":"2012","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27678","article-title":"Site-specific cancer deaths in cancer of unknown primary diagnosed with lymph node metastasis may reveal hidden primaries","volume":"132","author":"Hemminki","year":"2013","journal-title":"Int J Cancer."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv305","article-title":"Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","author":"Fizazi","year":"2015","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/eci.12062","article-title":"Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks","volume":"43","author":"Kamposioras","year":"2013","journal-title":"Eur J Clin Invest."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00402","article-title":"Does cancer of unknown primary (CUP) truly exist as a distinct cancer entity","volume":"9","author":"Bochtler","year":"2019","journal-title":"Front Oncol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21608\/ejhm.2021.165501","article-title":"Diagnostic value of napsin A in small biopsy of non-small cell lung carcinoma","volume":"83","author":"Samir","year":"2021","journal-title":"Egypt J Hosp Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"10317","DOI":"10.1038\/s41598-024-61087-2","article-title":"Novel therapeutic strategies for rare mutations in non-small cell lung cancer","volume":"14","author":"Gou","year":"2024","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a037812","article-title":"Molecular pathology of lung cancer","volume":"12","author":"J","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00733-6","article-title":"Rare molecular subtypes of lung cancer","volume":"20","author":"Harada","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0657","article-title":"Clinical, pathologic, and biologic features associated with BRAF mutations in non\u2013small cell lung cancer","volume":"19","author":"Cardarella","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2138","article-title":"Molecular pathways and mechanisms of BRAF in cancer therapy","volume":"28","author":"Poulikakos","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-230X(09)02001-6","article-title":"Ras signaling and therapies","volume":"102","author":"Young","year":"2009","journal-title":"Adv Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nsmb.2924","article-title":"Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation","volume":"22","author":"Thevakumaran","year":"2015","journal-title":"Nat Struct Mol Biol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e35781","DOI":"10.1002\/cncr.35781","article-title":"BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practice","author":"Parisi","year":"2025","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0836","article-title":"Developments in the space of new MAPK pathway inhibitors for BRAF-mutant melanoma","volume":"25","author":"Cohen","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.03.025","article-title":"Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non\u2013small cell lung cancer","volume":"132","author":"Facchinetti","year":"2020","journal-title":"Eur J Cancer."},{"key":"B26","doi-asserted-by":"publisher","first-page":"279ra41","DOI":"10.1126\/scitranslmed.aaa4691","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma","volume":"7","author":"Hu-Lieskovan","year":"2015","journal-title":"Sci Transl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0476-5","article-title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","volume":"25","author":"Ribas","year":"2019","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1082-2","article-title":"Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i","volume":"26","author":"Dummer","year":"2020","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"108592","DOI":"10.1016\/j.lungcan.2025.108592","article-title":"Induction therapy with dabrafenib, trametinib, and PD-1 inhibitor and surgical conversion in unresectable stage III non-small cell lung cancers with BRAF V600E mutation: 2 cases","volume":"205","author":"Cheng","year":"2025","journal-title":"Lung Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1666461\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:27:16Z","timestamp":1763360836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1666461\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1666461"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1666461","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"article-number":"1666461"}}